It is well established that activation of JAK/STAT signaling pathway, especially IL-6/JAK/STAT3 signaling pathway, drives tumor metastasis32,33 and promotes drug resistance in lung cancer.34–36 Thus, we speculate that IL-6/JAK/STAT3 signaling pathway may confer resistance to HOXC10 knockdown in KRAS-mutant lung cancer bone metastasis. Here, IL6 is linked to neoplasm.